ANTIBODY-DRUG CONJUGATE TARGETED THERAPY
Trodelvy is a combination prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic triple-negative breast cancer who have tried at least two other treatments. Trodelvy is also referred to by its drug name, sacituzumab govitecan-hziy.
Trodelvy is used as an immune targeted therapy for breast cancer. Trodelvy is a combination of drugs belonging to the classes of drugs called monoclonal antibodies and topoisomerase I inhibitor chemotherapies. Trodelvy is believed to work by binding to cancer cells and causing cell death from within.
How do I take it?
Prescribing information states that Trodelvy is given once weekly as an intravenous infusion (slow injection into your vein) by a healthcare professional. Trodelvy is usually given in a health clinic or doctor’s office. It should be administered according to the frequency specified by the physician.
Trodelvy is available only as an intravenous infusion.
The FDA-approved label for Trodelvy lists common side effects including nausea, neutropenia (low white blood cell count), diarrhea, fatigue, anemia (low red blood cell count), vomiting, hair loss, constipation, rash, decreased appetite, and abdominal pain.
Rare but serious side effects listed for Trodelvy include severe hypersensitivity reactions (exaggerated immune responses to antigens or allergens), very low white blood cell counts, severe nausea and vomiting, and fetal harm.
For more details about this treatment, visit:
Trodelvy — Gilead
Trodelvy — Breastcancer.org